KaloBios Pharmaceuticals, Inc. Appoints Martin Shkreli CEO and Announces New Financing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
KaloBios Pharma (KBIO) Receives NASDAQ Delisting Notice
November 23, 2015 5:46 PM ESTThe NASDAQ Stock Market notified KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), by letter dated November 17, 2015, that the Company is not currently in compliance with Nasdaqs continued listing requirement set forth in Rule 5250(c)(1) of the Nasdaq Listing Rules (the Rules), due to its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 (the 2015 Third Quarter 10-Q) with the Securities and Exchange Commission (the SEC).
Under the Rules, the Company has 60 calendar days from November 17, 2015 to submit a plan to Nasdaq to regain compliance with the Rules. The Company intends to file... More
Macrocure (MCUR) Ramps Higher
November 20, 2015 10:47 AM ESTMacrocure (NASDAQ: MCUR) shares advanced Friday, rising 50%. Some traders tied the moved to recent gains in KaloBios Pharma (NASDAQ: KBIO) and Macrocure's 'thin' 6.2 million share float.
... MoreNewly-Named KaloBios Pharma (KBIO) CEO Shkreli Briefly Comments on Twitter About Appointment
November 20, 2015 6:38 AM ESTIncoming KaloBios Pharma (NASDAQ: KBIO) CEO Martin Shkreli posted the following to Twitter late Thursday... More
KaloBios Pharma (KBIO) Names Martin Shkreli as CEO
November 20, 2015 6:16 AM ESTKaloBios Pharma (NASDAQ: KBIO) announced that an investor group led by Martin Shkreli, the Founder and Chief Executive Officer of Turing Pharmaceuticals AG, has acquired 70% of its outstanding shares. KaloBios also announced the appointment of Martin Shkreli to the position of Chief Executive Officer and his election as Chairman of the Board. In his new role, Mr. Shkreli will work with the company's senior management team to ensure the Company's continued operations. KaloBios further announced that David... More
